Topics
High-grade gliomas | Treatment | Clinical trials | BXQ-350
Home > Publications > Topics > High-grade gliomas > Treatment > Clinical trials > BXQ-350
Rixe O, Villano JL, Wesolowski R, Noonan AM, Puduvalli VK,
Wise-Draper TM, Curry R, Yilmaz E, Cruze C, Ogretmen B, Tapolsky
G, Takigiku R.
A first-in-human phase
1 study of BXQ-350, a first-in-class sphingolipid metabolism
regulator, in patients with advanced/recurrent solid tumors or
high-grade gliomas.
Clin
Cancer Res. 2024 Sep 12. doi:
10.1158/1078-0432.CCR-24-1721. PMID:
39264252. Interventional study˰
ˍ